LAS VEGAS – Analysis of data from a company that provides therapy for low testosterone showed that the treatment was not associated with a higher risk of myocardial infarction and stroke in men, and it may have played a protective role.
The findings clash with what two recent studies – one published in JAMA and the other in PLoS One – found, which showed that testosterone therapy increased the risk of MI and stroke in men, prompting the Food and Drug Administration to reassess the safety of the approved treatments.
Dr. Aaron Vinik, Murray Waitzer Endowed Chair for Diabetes Research at Eastern Virginia Medical School, Norfolk, puts the studies in perspective in this interview, and shares how patients should be treated based on current data and available knowledge.
nmiller@frontlinemedcom.com On Twitter @naseemsmiller